2023-12-27 08:27:59 ET
-
First Wave BioPharma FWBI +107% on plans to sell niclosamide program .
-
Cingulate ( CING ) +89% .
-
Cytokinetics CYTK +53% on positive Phase 3 data for heart disease therapy .
-
Jet.AI ( JTAI ) +38% .
-
Coherus Biosciences CHRS +34% after the FDA had approved an on-body injector version of the biosimilar – Udenyca for post-chemotherapy treatment Neulasta.
-
Bit Brother ( BETS ) +50% .
-
NKGen Biotech ( NKGN ) +21% after NKGen’s SNK01 program continues to show positive progress with the FDA IND clearance in October 2023 , and now the CTA clearance by Health Canada for a phase 1/2a clinical trial in moderate Alzheimer’s Disease patients .
-
Opthea Limited OPT +23% after it expects to receive the remaining $35 million committed funds under the Development Funding Agreement with Carlyle and Abingworth , and has entered into binding documentation with a new co-investor under an Amended DFA to secure an additional $50 million in funding.
-
Reneo Pharmaceuticals ( RPHM ) +16% .
-
Burford Capital ( BUR ) +12% .
-
BIT Mining ( BTCM ) +12% .
-
TeraWulf ( WULF ) +10% .
-
P3 Health Partners ( PIII ) +10% .
-
Cipher Mining ( CIFR ) +9% .
-
Altimmune ( ALT ) +8% .
-
Canaan ( CAN ) +7% .
-
HIVE Digital Technologies ( HIVE ) +6% .
-
Sphere 3D ( ANY ) +6% .
-
PLBY Group ( PLBY ) +6% .
-
Forafric Global ( AFRI ) +6% .
-
Bit Digital BTBT 5% after announcing the plans to double its operating fleet in its Bitcoin mining operations, to ~6.0 EH/s, during 2024.
-
See the biggest morning stock movers .
For further details see:
Cytokinetics, Burford Capital, Cipher Mining among premarket gainers' pack